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Research Recruitment Through US Central Cancer Registries: 
Balancing Privacy and Scientific Issues
| Laura M. Beskow, PhD, MPH, Robert S. Sandler, MD, MPH, and Morris Weinberger, PhD 
Cancer registries are a valu-
able resource for recruiting
participants for public health–
oriented research, although
such recruitment raises po-
tentially competing concerns
about patient privacy and par-
ticipant accrual.
We surveyed US central can-
cer registries about their poli-
cies for research contact with
patients, and results showed
substantial variation. The strat-
egy used most frequently
(37.5% of those that allowed
patient contact), which was
among the least restrictive, was
for investigators to notify pa-
tients’ physicians and then con-
tact patients with an opt-out ap-
proach. The most restrictive
strategy was for registry staff
to obtain physician permission
and contact patients with an
opt-in approach.
Population-based studies en-
hance cancer control efforts,
and registry policies can affect
researchers’ ability to conduct
such studies. Further discussion
about balanced recruitment ap-
proaches that protect patient
privacy and encourage benefi-






that is essential for identifying
public health priorities and for
planning and monitoring can-
cer-related programs.1–5 In the
United States, cancer reporting
occurs without patients’ con-
sent because of the collective
benefit derived from complete
case reporting. All 50 states
mandate cancer reporting, and
state authorities specify regula-
tions that govern central cancer
registries. Additionally, reg-
istries receive funding from 1
or both of 2 federal programs:
the Surveillance, Epidemiology,
and End Results (SEER) pro-
gram6 and the National Pro-
gram of Cancer Registries
(NPCR).7 Together, NPCR and
SEER registries collect cancer
data for virtually the entire US
population.
Cancer registries also play a
vital role in cancer research.
They provide not only statistical
data for analyzing patterns and
trends but also an unbiased
source of participants for popula-
tion-based studies. However, re-
cruiting research participants
through cancer registries raises
2 related concerns. First, investi-
gators could obtain personal in-
formation about individuals in
the registry before the individu-
als have agreed to participate in
the research, perhaps before
they are even aware that a can-
cer registry exists. Second, re-
cruitment strategies that maxi-
mize privacy protections (e.g.,
ensuring investigators have no
personal information about pa-
tients in the registry without
their permission) may compro-
mise participant accrual and,
thus, the validity and generaliz-
ability of research findings.
A key policy challenge is to
balance the needs of patients,
investigators, health care pro-
viders, and registries to protect
privacy while promoting the sci-
entific usefulness of registry.3
Cancer registries use a variety
of policies for addressing this
challenge:
• Educating patients about the
registry: Some registries use
passive methods (e.g., Web
sites and brochures displayed
in waiting rooms) to inform
the public about the registry.
Others actively notify individu-
als that information about
their cancer diagnosis has
been reported to the registry
and that researchers may con-
tact them.
• Involving treating physicians:
Some registries require physi-
cian permission before investi-
gators can contact patients,
and nonresponse is consid-
ered to be passive refusal.
Others require only physician
notification of planned patient
contact, and nonresponse is
considered to be passive
permission.
• Initiating patient contact: After
potential participants receive
an introductory letter about a
study, some registries require
an opt-in approach, where in-
vestigators follow-up only with
those patients who take an ac-
tion (e.g., return a postcard) to
indicate their interest. Others
allow investigators to follow-
up with all patients except
those who opt-out of further
contact.
Thus, procedures for identify-
ing and contacting potential re-
search participants through US
central cancer registries are not
uniform, and systematically col-
lected data about these proce-
dures are not available. We sur-
veyed cancer registries to define
the range of practice with regard
to recruitment for observational
research, including policies
about educating patients, involv-
ing physicians, and initiating
patient contact. We also asked
about rapid case ascertainment,
a critical process for many popu-
lation-based studies.8,9 A second-
ary objective was to elucidate
changes contemplated or imple-
mented in response to the
Health Insurance Portability and
Accountability Act (HIPAA) or
to privacy concerns in general.
Although HIPAA does not ob-
struct state laws that mandate
disease reporting for public
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TABLE 1—Cancer Registry Information (n=42)
No. (%)
Year registry established (mean = 1982; range = 1949–1999)
NAACCR certifieda
In 3 of last 3 years 26 (61.9)
In 2 of last 3 years 7 (16.7)
In 1 of last 3 years 2 (4.8)






State health department 29 (69.1)
University 10 (23.8)









Rapid case ascertainment capability
Yes 14 (33.3)
No 28 (66.7)
Note. NAACCR = North American Association of Central Cancer Registries; NPCR = National
Program of Cancer Registries; SEER = Surveillance, Epidemiology, and End Results program.
aGold or silver certification by the North American Association of Central Cancer Registries
in 2001 for 1999 incidence data, in 2002 for 2000 incidence data, or in 2003 for 2001
incidence data.
health purposes (45 CFR
164.203), it has brought atten-
tion to the issue of health infor-
mation privacy.
METHODS
We drafted a survey instru-
ment on the basis of state can-
cer registry laws and regula-
tions, literature about cancer
registries, and literature about
research recruitment. We re-
vised the survey after a review
by experts in cancer registration;
cancer epidemiology; and health
law, policy, and ethics. We then
submitted an application to
survey members of the North
American Association of Central
Cancer Registries (NAACCR),10
an umbrella organization that
includes all US and Canadian
central cancer registries. The
NAACCR board of directors
approved our application in
January 2004, and board mem-
bers from US registries—in their
capacity as registry directors—
pretested the survey and offered
their feedback. The final survey
(available from the correspon-
ding author) comprised 40
questions and included a section
for comments and clarification.
Additionally, respondents were
asked to review and correct in-
formation we had obtained in a
summary of the main survey re-
sults (available from the corre-
sponding author).
In May 2004, we used a
NAACCR e-mail distribution list
to send the survey electronically
to the directors of 59 registries:
each of the 50 state registries,
the District of Columbia registry,
and SEER area registries in
Alaska, California (three reg-
istries), Georgia, Michigan, Okla-
homa, and Washington. A re-
minder was e-mailed 3 weeks
later, and a second reminder was
sent by US mail with signature
confirmation 6 weeks later. Data
were analyzed with Stata soft-





Surveys were completed by
42 of the 59 (71.2%) invited reg-
istries, including 38 of 51
(74.5%) statewide and District of
Columbia registries, and 4 of 8
(50%) SEER area registries. Ac-
cording to publicly available in-
formation,6,7,10 nonresponding
registries were older than re-
sponding registries (mean year
established 1972 vs 1982;
P=0.01), but there were no sig-
nificant differences in federal
funding source (any SEER fund-
ing vs NPCR funding only) or
NAACCR certification (a dichoto-
mous variable reflecting data
quality).
Among responding registries,
NPCR was the most common
source of federal funding for
basic registry operations. Most
were housed in their state’s
health department; other loca-
tions included universities, a
cancer center not affiliated with
a university, a hospital associa-
tion, and a tribal government
(Table 1). However, even when
not housed in the health depart-
ment, state laws and regulations
generally govern registries’ activ-
ities, including whether and how
patients may be contacted for
research purposes.
Patient Education
Active and passive education.
Thirty (71.4%) registries used
passive approaches to patient
education; 5 of these registries
also used active approaches with
at least 1 subset of patients
(Table 1). Among the 5 reg-
istries that used active educa-
tion, 3 said the registry most
often informed patients about
cancer reporting. Two said the
diagnosing provider or facility
most often informed patients, al-
though 1 noted it had no re-
sources for enforcement and
was aware that the requirement
was regularly not applied.
Between 2000 and 2004, 2
registries made or considered a
change in their approach to pa-
tient education. The North Car-
olina registry was the only re-
spondent that said HIPAA
concerns (and privacy concerns
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TABLE 2—Research Contact With Patients Among Respondents
Who Allowed Contact (n=33)
No. (%)a
Is physician involved in recruitment process?
Yes, required 25 (75.8)
Yes, strongly recommended 4 (12.1)
No 4 (12.1)
If yes (n = 29), physician contacted by
Investigator 17 (58.6)
Registry staff 11 (37.9)





Registry staff 12 (36.4)
Patient response
Opt out 21 (63.6)
Opt in 11 (33.3)
aPercentages may not sum to 100% because of missing information.
in general) were a primary moti-
vation; in 2003, it implemented
a policy of active education for
the subset of patients who were
identified as potentially eligible
for a particular study.
Before July 2001, patients in
Virginia were not actively noti-
fied; from July 2001 to July
2003, state law required the reg-
istry to notify patients that it had
received information. However,
effective July 2003, the law
(§32.1-71.02) was changed to
make the diagnosing physician
responsible for notifying patients.
The reported motivations for this
change were multiple negative
consequences that resulted from




seven (64.3%) registries had ed-
ucational materials, including
brochures, pamphlets, or infor-
mation sheets (88.9%); Web
pages specifically designed for
patients and the public (70.4%);
and other items, such as annual
reports and community outreach
activities (18.5%). Although 15
(35.7%) registries did not have
educational materials, passive ed-
ucation may still occur through
laws that require lists of re-
portable conditions be made
available to the public. For exam-
ple, Florida law requires hospi-
tals to provide notification of the
reportability of cancer. The Flor-
ida Cancer Data System also re-
quires researchers to include dis-
closures about the registry in
their initial mailing to patients
and to ensure that study person-
nel provide a clear description of
cancer registration in the state.11
Disclosures about the possibility
of researcher contact. Of the 21
registries that had patient educa-
tion materials and allowed pa-
tient contact (see next section),
14 (66.7%) said their materials
described the possibility that re-
searchers may contact patients
about participating in a study. Of
these, 1 said patients were spe-
cifically asked to let the registry
know whether they were willing
to be contacted, and another
said patients were told they
could inform the registry if they
did not want to be contacted.
The majority (78.6%) said the
disclosure included only a gen-
eral statement about how to con-





Allowing contact for research
purposes. Thirty-three (78.6%)
responding registries said con-
tact with patients was allowed
for the purposes of research re-
cruitment (Table 1). These reg-
istries reported a total of 171
observational studies (mean=
5.9; range=0–15) for which
potential participants had been
identified through their registry
between 2000 and mid-2004.
Research approvals. Of the 33
registries that allowed patient
contact, all reported 1 or more
approval processes. These in-
cluded approval by the institu-
tional review board of the inves-
tigator’s home institution (87.9%);
the institutional review board or
other research committee associ-
ated with the registry (78.8%); a
specific person associated with
the registry, for example, the di-
rector (57.6%); and other ap-
provals, for example, from an ad-
visory committee (39.4%). One
registry required approval by the
institutional review board of each
reporting facility in the proposed
study area.
Physician involvement. Of the
33 respondents that allowed
patient contact, 29 (87.9%) re-
quired or strongly recom-
mended contact with patients’
physicians before contact with
patients (Table 2); however, ap-
proximately 20% did not rou-
tinely collect information that
identified patients’ physicians.
Several noted that a physician
code was collected only if hospi-
tals chose to report it; further-
more, although registries en-
couraged hospitals to use a
physician license number that
would have meaning statewide,
most used hospital-specific
codes.
Of the 29 registries that in-
volved physicians, most (58.6%)
allowed researchers to contact
patients’ physicians, and the ma-
jority (82.8%) used physician
notification (Table 2). Among
those that used notification, the
mean length of time allowed for
physician response was 2.7
weeks (range=2–4 weeks).
Between 2000 and 2004, 5
registries made or considered a
change in physician involvement,
all of which were toward less
physician involvement. The
Massachusetts and North Car-
olina registries both changed
from physician permission to
physician notification (in 2000
and 2003, respectively); the
Louisiana and Utah registries
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were considering such a change.
In 2001, the Wisconsin registry
changed from physician permis-
sion to physician notification and
was considering a further change
to no involvement. With the ex-
ception of North Carolina, nei-
ther HIPAA nor general privacy
concerns were primary motiva-
tions. One registry described a
general sense that physicians
should not have the right to de-
cide if patients can be contacted.
The North Carolina registry
noted some physicians were con-
cerned about whether actively
providing permission for re-
searcher contact with patients—
rather than being notified but not
required to respond—could be a
violation of HIPAA.
Initiating patient contact. After
a research project was approved,
and physician input was obtained,
if applicable, most (60.6% of the
33 that allowed patient contact)
allowed investigators to initiate
contact with patients (Table 2).
Most (63.6%) also allowed an
opt-out approach.
Three registries made a
change in how patients were
contacted between 2000 and
2004. The Kentucky registry,
citing both HIPAA and general
privacy concerns, implemented
procedures in 2003 that allow
patients to either participate in
research projects or ask that
their names not be released.
The New Jersey registry said
that, although it occasionally al-
lowed investigators to contact
patients before 1999, it imple-
mented procedures in 2002
that require registry staff to initi-
ate contact because of general
privacy concerns.
Patient preferences about re-
searcher contact. Respondents
were asked to estimate the per-
centage of patients reported be-
tween 2000 and 2004 who
were flagged to prevent re-
searcher contact between 2000
and 2004. Patients communi-
cated this preference to the
registry in response to either
disclosures in educational mate-
rials or having been contacted
by researchers. Of the 33 re-
spondents that allowed patient
contact, 10 (30.3%) said no pa-
tients were flagged; 17 (51.5%)
said less than 1% of patients
were flagged; and 3 (9.1%) said




(95.2%) said laws or regulations
in their state required that cancer
cases be reported within 6
months of diagnosis, treatment,
or discharge. Fourteen (33.3%)
had rapid case ascertainment ca-
pability (Table 2). The average
definition of rapid was within 44
days of diagnosis (range=30–90
days). Of the registries that had
rapid-reporting capability, 4
(28.6%) said more than 10% of
cases were reported by entities
either not willing or not able to
participate in rapid case ascer-
tainment. Five (35.7%) said 1%
to 10% of cases were reported
by such entities, and 1 (7.1%)
said less than 1% of cases had
been reported by such entities.
DISCUSSION
Population-based studies im-
prove the public’s health through
the development of new knowl-
edge about cancer etiology, out-
comes, and quality of care, and
investigators have begun to use
cancer registries to identify and
contact potential participants for
such research.12–16 However, re-
search recruitment through can-
cer registries raises scientific and
ethical concerns.
Investigators’ ability to iden-
tify, contact, and achieve high
participation rates among poten-
tial participants increases the va-
lidity and the generalizability of
findings.17 These recruitment ac-
tivities must take place within the
context of well-established re-
quirements for ethically responsi-
ble research,18–20 which include
an obligation to minimize risks to
participants. When assessing
risks, however, it is important to
distinguish between risks associ-
ated with recruiting participants—
identifying and contacting indi-
viduals about their interest in
research participation—and risks
associated with participating in
the research.21 When contacted
by researchers, individuals have
a number of options, including
not responding, expressing disin-
terest at the outset, or learning
more about the research and
making an informed decision
about whether to take part.
The primary risk associated
with research recruitment
through cancer registries is inva-
sion of privacy, which can some-
times rise to the level of serious
harm (e.g., insurance or employ-
ment discrimination) if sensitive
medical information is misused.
Harm also might ensue if infor-
mation of personal significance is
introduced as part of the offer to
participate in research. For exam-
ple, some patients listed in a can-
cer registry may be unaware of
their diagnosis before researcher
contact.
Invasion of privacy also can
be a wrong rather than a
harm.22 Wrongs are generally
seen as less grievous than harms,
because wrongs seldom touch on
matters of physical or even emo-
tional well-being.22 When re-
searchers recruit through cancer
registries, an individual may per-
ceive that his or her privacy has
been invaded when an investiga-
tor gains access to personal in-
formation before that person has
agreed to participate in the re-
search. Although such an inva-
sion may be contrary to some
patients’ preferences about
whether and how they are con-
tacted, it does not necessarily re-
sult in harm. Committing a
wrong against a person violates
the ethical principle of respect
for persons, that is, allowing indi-
viduals to make autonomous
choices rather than imposing
choices upon them.22 At the
same time, every person who
seeks medical or preventive care
is a direct beneficiary of the
knowledge and insights gained
from research.23
Our survey sought to describe
strategies cancer registries use to
address these potentially com-
peting concerns. The results
showed substantial variation
across registries. Approximately
20% did not allow research con-
tact with patients. Of the reg-
istries that did, 9 of the 12 theo-
retically possible models for
research recruitment were actu-
ally used (Figure 1). The most
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Note. This figure depicts recruitment models from the 33 (78.6%) registries through which research contact with patients was allowed; 9 (21.4%)
registries did not allow such contact.
The number below each “branch” is the number of registries in that category.
The percentage above each branch is the proportion of registries from the immediately preceding node that were in that category. The
percentages for the set of branches emanating from each node may not total 100% because of missing information. The percentages at the far
right are the proportion of registries that used the model defined by following that branch back to the far left of the diagram.
FIGURE 1—Models for research recruitment through cancer registries.
common model, which is among
the least restrictive, allows inves-
tigators to notify patients’ physi-
cians and then contact patients
with an opt-out approach. Reg-
istries that used this model at the
time of the survey accounted for
76 (44.4%) of the 171 studies
that were conducted between
2000 and mid-2004. In com-
parison, registries that used the
most restrictive model (registry
staff obtain physician permission
and then contact patients with
an opt-in approach) accounted
for only 9 studies (5.3%).
Our secondary objective was
to elucidate any effect of HIPAA
on registry recruitment policies.
Approximately 15% of respond-
ing registries reported changes in
patient education, and nearly
25% reported changes in proce-
dures for patient contact. Most
changes were motivated by pri-
vacy concerns in general rather
than HIPAA requirements per
se—appropriately so, because
cancer registries are not covered
entities under HIPAA.
A strength of our study was
the high response rate for a sur-
vey covering a broad array of
policies that had not been empir-
ically documented. We relied on
face validity when constructing
the survey; however, validity was
strengthened by review and feed-
back from a multidisciplinary
group of experts. It was further
enhanced by providing respon-
dents the opportunity to review
their answers in the context of a
registry-by-registry summary of
the main survey findings.
Because of the prevalence
and the public health conse-
quences of cancer, and the atten-
dant need for population-based
studies,24,25 further research on
the ethical and scientific accept-
ability of various approaches to
research recruitment through
cancer registries is important.
For example, research is needed
on the most effective and effi-
cient ways of educating patients
about the registry and the possi-
bility of researcher contact. Be-
cause cancer cases are reported
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without patients’ consent, many
patients may be surprised not
only to be contacted by a re-
searcher but also to learn that a
registry exists that collects their
information. Ideally, educational
efforts would remedy this lack of
awareness and, thus, be an im-
portant precursor to research re-
cruitment. At the same time,
cancer registries have limited re-
sources, and patients who are
dealing with a recent cancer
diagnosis may not read or even
recall receiving educational
materials.26,27
Research also is needed on
the role of the treating physician
during research recruitment.
This research should address
(1) physicians’ motivations for
whether and how they respond
to investigator requests and
whether they prefer to be asked
permission, notified, or not in-
volved; (2) patients’ knowledge
and preferences about physician
involvement; and (3) investiga-
tors’ insights and experiences,
including the effect of physician
involvement on study participa-
tion rates.
One advantage to physician
involvement is that physicians
can help manage privacy risks.
If registry staff contact physi-
cians and physicians in turn
contact patients to determine
their interest, the patient can
elect whether or not to be con-
tacted by the investigator with-
out the investigator knowing
any personal details a priori.
Often, however, investigators
are given such details: we found
investigators, rather than reg-
istry staff, were usually respon-
sible for contacting physicians
and patients. Furthermore,
whether contacted by registry
staff or investigators, the physi-
cian is generally not bound by
procedural requirements. As
noted by Gurwitz et al., if the
physician does not ask what the
patient’s wishes are, it may be
the physician’s “own perceptions
regarding a constellation of
medical and psychosocial char-
acteristics, as well as personal
biases, that determine whether
approval is given to contact a
patient.” 28(p1344) When physi-
cians do communicate with the
patient about the study before
researcher contact, there are
concerns about how the study is
presented29 and whether the
patient may feel pressured to
participate.30
Another advantage to physi-
cian involvement is that physi-
cians can help researchers ex-
clude patients who are deceased,
too ill, or otherwise ineligible.
However, the ability to provide
such information assumes an es-
tablished physician–patient rela-
tionship that may not always
exist. According to our results,
many registries do not routinely
collect information that identifies
patients’ physicians. Therefore,
the physician of record that is
available to researchers is often
the surgeon listed on the pathol-
ogy report, who may have no on-
going responsibility for the pa-
tient’s care.
Physician involvement may
have a positive influence on
some patients,29,31 although oth-
ers may view it as unnecessary
or even paternalistic.32,33 From
an investigator’s perspective, phy-
sician involvement may facilitate
effective physician–researcher re-
lationships,31 but specifically ob-
taining physician permission can
be expensive and time-consum-
ing.31,34,35 Placing the physician
in the role of “gatekeeper” may
have an adverse effect on partici-
pant accrual for otherwise bene-
ficial research, which is itself an
ethical concern.21
Finally, research is needed on
the impact of alternative ap-
proaches to initiating patient con-
tact. Whether patients are asked
to opt in or opt out of learning
more about a study has implica-
tions for both privacy and ac-
crual. On the basis of studies that
used an opt-out approach,36,37 it
appears that very few individuals
take action to prevent further re-
searcher contact and that a rela-
tively low proportion of those
who do not opt out are in fact
not interested. The probability
and magnitude of harm that may
result from an opt-out approach
must be weighed against the loss
of research benefits that may re-
sult if a more restrictive opt-in
approach is required.21
Future research should exam-
ine the preferences of various
stakeholders, including patients,
physicians, investigators, and
cancer registries, as well as the
outcomes of different ap-
proaches with respect to privacy
and participant accrual. Protect-
ing patient privacy and support-
ing beneficial research need not
be mutually exclusive goals; in-
deed, appropriate protections
promote public confidence in,
and support for, the research
enterprise.38 Care must be
taken to both protect patients
and avoid overly restrictive
policies that have a chilling ef-
fect on research and limit op-
portunities for patients who
would like to participate.
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